Study shows ivonescimab improves progression-free survival in EGFR+ lung cancer

For patients with non-small cell lung cancer with the epidermal growth factor receptor (EGFR) variant, ivonescimab plus chemotherapy improves progression-free survival, according to a study published online May 31 in the Journal of the American Medical Association (JAMA) to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Wenfeng Fang, M.D., Ph.D., from the Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues compared the efficacy of ivonescimab plus chemotherapy to chemotherapy alone for patients with relapsed Read More

Related posts:

  1. Radioligand therapy extends progression-free survival with manageable safety profile in advanced prostate cancer
  2. Study links neighborhood violence, lung cancer progression
  3. Trial shows mistletoe extract does not increase survival in advanced pancreatic cancer
  4. Comparative analysis shows FAPI PET/CT improves staging of newly diagnosed breast cancer
  5. Sorting therapeutic stem cells by function improves healing after heart attack, lab study shows
  6. New cancer treatment slows progression of aggressive neuroendocrine tumors, study finds
  7. CARM1 drives triple-negative breast cancer progression by coordinating with HIF1A: Study
  8. Study finds just 18% of people who need lung cancer screening get it

Leave a Reply

Your email address will not be published. Required fields are marked *